CompletedNot Applicable

Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH

France389 participantsStarted 2015-08

Plain-language summary

The purpose of the study is to assess the fibrin structure marker in the plasma of cancer patients, treated or not treated with LMWH at prophylactic or therapeutic doses, in order to determine the venous thromboembolic risk. The occurrence of thromboembolic events in patients without treatment and in patients under LMWH treatment will be recorded, depending on the location and type of cancer, metastases, and treatment of cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with non-opposition to participate in the evaluation * patients from Internal Medicine Department * patients affected with all types of malignancies, treated or not with LMWH Exclusion Criteria: * patients treated with VKA or with recent surgery (within one month) * patients with a condition known to cause a coagulation activation status other than cancer (sepsis, pneumonia,..)

What they're measuring

Dynamic evolution of the optical density delta (ODD)

Timeframe: 36 Months

Trial details

NCT IDNCT02552381

SponsorDiagnostica Stago R&D

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-12-20

View on ClinicalTrials.gov More Malignant Tumor trials